Stockscreener 앱 받기
100.68
1.87%
1.85
시장 영업 전:
100.28
-0.40
-0.40%
전일 마감가:
$98.83
열려 있는:
$101
하루 거래량:
19.81M
Relative Volume:
1.46
시가총액:
$175.37B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
28.05
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
+7.19%
1개월 성능:
+13.76%
6개월 성능:
-17.31%
1년 성능:
-16.46%
1일 변동 폭
$99.47
$102.13
1주일 범위
$87.64
$102.13
52주 변동 폭
$81.97
$137.49
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
100.68 | 172.14B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
319.87 | 126.97B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.20 | 106.96B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.03 | 66.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.73 | 50.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Laboratories Cybersecurity Breach Analysis: ShinyHunters Attack on Exact Sciences Systems and ShadowByt3$ LabCentral Portal Incident - Rescana
Abbott Laboratories stock holds firm as diagnostics and medical devices support earnings - ad-hoc-news.de
Medical giant Abbott investigates two cyber incidents as ShinyHunters claims breach - Cybernews
This Dividend ETF Yields 3.2% and Is Beating the Nasdaq-100 This Year - The Motley Fool
Abbott Laboratories (ABT) Stock Faces Margin Squeeze As Net Profit Slide Tests Growth Narrative - simplywall.st
Abbott Stock: Bear Trap Over, With Richer Return Prospects (NYSE:ABT) - Seeking Alpha
Abbott Just Showed Its Growth Engine Has More Than One Cylinder - Trefis
Abbott investigates two separate cyber incidents, says no operations affected By Reuters - Investing.com
Abbott investigates two cyber intrusions targeting cancer diagnostics and LabCentral portal - Межа. Новини України.
Abbott investigates two separate cyber incidents, says no operations affected - Reuters
Abbott Investigates Two Separate Cyber Incidents, Says No Operations AffectedU.S. News - U.S. News - Money
Keysight Invalidates IRS Rule On GILTI, Abbott Says - Law360
US companies face rise in cyber attacks - Reuters
Abbott probes two cyber incidents amid extortion claims - BleepingComputer
Abbott discloses cyberattack on cancer diagnostics business - MedTech Dive
ABT Reiterated by Piper Sandler -- Price Target Raised to $118 - GuruFocus
Can Abbott Laboratories (NYSE:ABT) Extend Its Dividend Strength? - Kalkine Media
Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance - TIKR.com
Bernstein Adjusts Price Target on Abbott Laboratories to $117 From $110, Maintains Outperform Rating - Moomoo
Abbott Laboratories Stock (ABT) Moved Up by 3.03% on Jul 17: Drivers Behind the Movement - TradingKey
ABT Q2 Earnings Call Flags Stronger Second-Half Setup - The Globe and Mail
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results - Benzinga
Benchmark reiterates Buy on Abbott Labs stock, keeps $120 target - Investing.com
Can Abbott Stock Deliver on Its Second-Half Growth Promise? - Trefis
Abbott Laboratories stock could rise 40%+ by 20... - Pluang
JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $112, Maintains Outperform Rating - marketscreener.com
Abbott Laboratories: Pick Up This Dividend King Deal Now - Seeking Alpha
Raising Dividends for 54 Consecutive Years to Reward Shareholders, Abbott Laboratories’ Diversified Layout Consolidates Its Growth Foundation - NAI500
What Helped Abbott Laboratories (NYSE:ABT) Raise Full-Year Outlook? - Kalkine Media
Abbott Laboratories (ABT) Could Be 15% Undervalued On Raised 2026 Earnings Outlook - simplywall.st
Why Abbott Stock Jumped Today - The Motley Fool
Abbott Laboratories Earnings Call Signals Broad-Based Momentum - TipRanks
ABT: Abbott Laboratories Exceeds Revenue and EPS Expectations, R - GuruFocus
Abbott Is On Deck to Launch Several New Devices - Morningstar
ABT: Abbott Laboratories Exceeds Expectations and Raises Profit Outlook - GuruFocus
Abbott Laboratories’s Stock Price Soars to $98.83, Enjoying a Robust 10.71% Uptick - Smartkarma
BTIG raises Abbott Labs stock price target to $134 on Q2 strength - Investing.com
Strong Demand and Growth Forecast for Abbott Laboratories (ABT) - GuruFocus
Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Stro - GuruFocus
Abbott (ABT) Lifts 2026 EPS Outlook Amid Business Mix Shift Toward Devices and Diagnostics - Yahoo Finance
Abbott (ABT) Receives Outperform Rating Amid Positive Q2 Results - GuruFocus
Abbott Surges 11% After Boosting 2026 Profit Outlook - Investor's Business Daily
Abbott Laboratories Stock Draws Fresh Targets As Growth Story Builds - StocksToTrade
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune
Abbott Laboratories (ABT) Surges on Upbeat Q2 Earnings and Revis - GuruFocus
Wells Fargo Raises Abbott Laboratories Price Target to $112 From $109 - marketscreener.com
Abbott Stock Is Leading the S&P 500 After Earnings for Its Best Day in 24 Years - Barron's
How Abbott Laboratories (ABT) performed in Q2 2026 - AlphaStreet
Abbott Labs Draws Bullish Targets As Legal Overhang Fades - timothysykes.com
Market movers: AtaiBeckley, UnitedHealth Group, Abbott Laboratories, Medicus Pharma… - Proactive financial news
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.42%
자본화:
|
볼륨(24시간):